{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-002289","form_type":"8-K","ticker":"MLAB","cik":"0000724004","company_name":"MESA LABORATORIES INC /CO/","filed_at":"2022-02-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:09.565494+00:00","generated_at":"2026-06-27T12:01:02.251745+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Mesa Labs Q3 revenue up 60% to $54.7M; GAAP operating loss $2.5M on Agena acquisition costs","bullets":["Q3 revenue $54.7M (+60% YoY); organic revenue growth 12%.","GAAP operating loss $2.5M; net loss $0.39/diluted share.","Non-GAAP adjusted op. income $7.1M; excl. unusual items $13.8M (+73%).","Biopharma division organic growth 46%; Calibration Solutions revenue fell 6%.","Acquired Agena Bioscience in Oct 2021; cash reserves fell from $264M to $52M."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-002289","json":"https://secwatch.observer/filing/0001437749-22-002289.json","markdown":"https://secwatch.observer/filing/0001437749-22-002289.md","text":"https://secwatch.observer/filing/0001437749-22-002289.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/724004/000143774922002289/0001437749-22-002289-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/724004/000143774922002289/mlab20220201_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T12:01:02.251745+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}